Recent News

• 04.16.2025 - Sonnet Releases Virtual Investor "What This Means" Segment
• 04.04.2025 - Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose
• 04.01.2025 - Sonnet Announces Release of Corporate Update Video
• 04.01.2025 - Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.
• 03.26.2025 - Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas
• 03.19.2025 - Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein
• 03.11.2025 - Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
• 02.26.2025 - Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors
• 02.19.2025 - Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates
• 02.18.2025 - Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Recent Filings

• 04.04.2025 - 8-K Current report
• 04.01.2025 - 8-K Current report
• 03.26.2025 - 8-K Current report
• 03.19.2025 - EX-99.1 EX-99.1
• 03.19.2025 - 8-K Current report
• 02.26.2025 - EX-99.1 EX-99.1
• 02.26.2025 - 8-K Current report
• 02.21.2025 - 3 Initial statement of beneficial ownership of securities
• 02.19.2025 - EX-99.1 EX-99.1
• 02.19.2025 - 8-K Current report